Loading…
← CockpitCompetitor Analysis › 7729.TWO Steminent Biotherapeutics, Inc.Open in the cockpit ↗

Steminent Biotherapeutics, Inc.7729.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Biotechnology
Momentum leader 100
Mkt cap
$668M
US dollars, full cap
$/day
$8.12M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-98.2 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · TWDNT$290.00
1D+10.7%
1W+17.4%
1M+50.3%
3M+266.6%
6M+291.9%
YTD+389.9%
1Y+637.9%
ATR %8.0%
52w lowhigh3.6% off high

What Steminent Biotherapeutics does

No business profile yet.

Steminent Biotherapeutics at a glance

Size Steminent Biotherapeutics (7729.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $668M, the 341st largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$290.00 on 18 Nov 2026.

Performance Over six months the shares gained 291.9%, against -17.6% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 2nd highest of 19 in its peer set.

Capital Return on invested capital runs 98.2 points below its cost of capital (5.0% WACC).

Relative performance

10020030040021 May 202621 Aug 202618 Nov 20267729.TWO 385Peer median 82
Six months, rebased to 100: Steminent Biotherapeutics against the median of its 20 peers (local-currency closes).

Steminent Biotherapeutics financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$0NT$0NT$0NT$941,000NT$636,000
Revenue growth——-100%+48%—
Gross profit-NT$31.8M-NT$30.9M-NT$16.4M-NT$12.7M-NT$18.3M
EBITDA-NT$177M-NT$143M-NT$146M-NT$119M-NT$88.8M
Net income-NT$204M-NT$174M-NT$159M-NT$129M-NT$85.5M
Free cash flow-NT$179M-NT$140M-NT$227M-NT$142M-NT$71.5M
Capital expenditureNT$5.12MNT$7.76MNT$88.4MNT$27.7MNT$2.51M
Total debtNT$65.2MNT$77.4MNT$63.8MNT$75.4MNT$55.2M

Quarterly statements and history in the cockpit →

Steminent Biotherapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+500%+1,000%0%+50%9966KURA688221688197301520GERNJANXATTOSRZNAURA7729.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Steminent Biotherapeutics is the large dot.

Steminent Biotherapeutics competitors and peer comparison

How Steminent Biotherapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Steminent Biotherapeutics against its 20 peers (data as of 18 Nov 2026)
Measure7729.TWOPeer medianRank in peer set
1-month return+50.3%-7.3%highest of 21
6-month return+291.9%-17.6%2nd highest of 19
Distance from 52-week high-3.6%-44.8%highest of 21
ROIC minus cost of capital-98.2 pp-11.3 pplowest of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Steminent Biotherapeutics 7729.TWOTaiwan$668M+292%n/an/an/an/an/a
Alphamab Oncology 9966.HKHong Kong$666M-38%-32%-38%6.7×n/an/a
Kura Oncology KURAUnited States$674M-29%-24%-394%2.6×n/an/a
Frontier Biotechnologies 688221.SSChina$658M-48%+153%-20%11.4×40.3%+21.5%
Shouyao Holdings Beijing 688197.SSChina$653M-26%+4,564%-92%38.1×n/an/a
Anhui Wanbang Pharmaceutical Technology 301520.SZChina$684M+74%-15%-8%14.7×44.8%+14.7%
Prime Medicine PRMEUnited States$695M+35%+18%-2,584%105.4×n/an/a
Geron GERNUnited States$638M-21%+19%-8%2.8×n/an/a
Shenzhen Weiguang Biological Products 002880.SZChina$633M-27%0%18%4.4×n/an/a
Janux Therapeutics JANXUnited States$631M-28%+133%-599%n/an/an/a
Solid Biosciences SLDBUnited States$709M-2%n/an/an/an/an/a
Attovia Therapeutics ATTOUnited States$710M+1,325%n/a-5,945%220.7×n/an/a
Getein Biotech 603387.SSChina$625M-13%+8%21%2.6×-8.9%-1.3%
Shaanxi Micot Pharmaceutical Technology 2335.HKHong Kong$715Mn/an/an/an/an/an/a
R&G PharmaStudies 301333.SZChina$722M-11%+21%11%3.4×17.3%+11.8%
Apnimed APMDUnited States$726Mn/a+380%-140%10.8×n/an/a
Design Therapeutics DSGNUnited States$606M-15%n/an/an/an/an/a
Beijing SL Pharmaceutical 002038.SZChina$736M-20%-4%-119%6.9×-13.5%-10.9%
Surrozen SRZNUnited States$605M+17%+192%-485%48.5×n/an/a
Anhui Huaheng Biotechnology 688639.SSChina$605M-45%+7%3%1.9×n/an/a
Aura Biosciences AURAUnited States$743M-4%n/an/an/an/an/a

Questions

Which companies are Steminent Biotherapeutics's closest peers?
The cockpit's peer set: Alphamab Oncology (9966.HK), Kura Oncology (KURA), Frontier Biotechnologies (688221.SS), Shouyao Holdings Beijing (688197.SS), Anhui Wanbang Pharmaceutical Technology (301520.SZ), Prime Medicine (PRME), Geron (GERN), Shenzhen Weiguang Biological Products (002880.SZ).
How has Steminent Biotherapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +291.9% against -17.6% for the median peer; over one year +637.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.